The Earthtimes online News
Home

Zacks Analyst Blog Highlights: Epicor Software, Oracle, SAP, SurModics and Merck & Co.

Posted : Fri, 27 Jun 2008 10:00:40 GMT
Author : IL-ZACKS.COM
Category : Press Release
News Alerts by Email click here )
Create your own RSS
News | Home
CHICAGO - (Business Wire) Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Epicor Software Corp.'s (Nasdaq: EPIC), Oracle (Nasdaq: ORCL), SAP (NYSE: SAP), SurModics, Inc. (Nasdaq: SRDX) and Merck & Co. (NYSE: MRK).

See the latest posts to the Analyst Blog: http://www.zacks.com/blog/post_info.html?g=6

Here are highlights from Thursdays Analyst Blog:

Intense Market for Epicor Software

Epicor Software Corp.'s (Nasdaq: EPIC) strategy is to create enterprise software applications on industry-standard technologies to lower the total cost of ownership and to respond swiftly to next-generation demands. Another important part of Epicor's strategy is to provide vertical solutions that can be tailored for midsized companies.

However, the company operates in an intensely competitive landscape. It faces competition from large, multinational ERP vendors such as Oracle (Nasdaq: ORCL) and SAP (NYSE: SAP). These firms have greater financial resources and are moving aggressively towards acquiring a market niche.

Expenses Accompany SurModics

SurModics, Inc. (Nasdaq: SRDX) provides surface modification and drug delivery technologies to medical device and pharmaceutical companies. Acquisition of profitable companies and the I-vation deal with Merck & Co. (NYSE: MRK) and growth in other operating segments have enabled the company to reduce its dependence on Cypher stent sales.

Going forward, the diversified revenue stream should enable the company to post sustainable growth. However, higher operating expenses accompany the shift in the company's revenue base. As such, we maintain our Hold rating on the stock with a target price of $49.00.

Get the full analysis of all these stocks by going to http://at.zacks.com/?id=2649.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=2677

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Zacks.com
Terry Ruffolo
Media Relations
312-265-9213
Visit: www.zacks.com


Copyright © 2008 Business Wire. All rights reserved.



Article : Zacks Analyst Blog Highlights: Epicor Software, Oracle, SAP, SurModics and Merck & Co.
Print this article
Share this article

Stay Updated

News gadget on your Google homepage
Subscribe to a news feed in Google Reader
Share on

Have your Say
Name
Email
Subject
Your Comment

Enter Verification code
 
  

 


Choose Theme
Green Earth Blue Earth Orange Earth Purple Earth

Search
 
You can

Current News

News Category
Business
Entertainment
Environment
General
Health
Sports
Technology
World
Add to Google Toolbar
Breaking News
Press Releases

About us | News Archives | Browse old Archive | Feedback | Disclaimer | Mobile/PDA | News Alerts

The views expressed in the articles are not necessarily those of earthtimes.org and we accept no responsibility for the views or opinions
expressed in the articles either direct or indirect.

© 2008 www.earthtimes.org, The Earth Times, All Rights Reserved | Privacy Policy